Literature DB >> 1868054

Structural elucidation and antigenicity of a novel phenolic glycolipid antigen from Mycobacterium haemophilum.

G S Besra1, M McNeil, D E Minnikin, F Portaels, M Ridell, P J Brennan.   

Abstract

The structure of a novel antigenic glycolipid that distinguishes the opportunistic pathogen Mycobacterium haemophilum from all other mycobacteria was established by a series of degradation reactions leading to products that were analyzed by gas/liquid chromatography-mass spectrometry. The complete structure of the oligosaccharide unit was determined as 2,3-di-O-CH3-alpha-L-Rhap(1----2)3-O-CH3-alpha-L-Rhap(1----4 )-2,3-di-O-CH3-alpha-L-Rhap(1----. The lipid portion of the phenolic glycolipid was composed of two component phenolphthiocerols differing by two methylene groups, as determined by analysis of their per-O-trideuteriomethylated derivatives. The diol unit of the phenolphthiocerols has a threo relative configuration. The absolute stereochemistry of the asymmetric centers of the phenolphthiocerols is uncertain, but the centers are probably 3R, 4S, 9R, and 11R as found for phthiocerol A from Mycobacterium tuberculosis. The hydroxyl functions of the branched glycolic chain are esterified to a complex mixture of multi-methyl branched mycocerosic acids, C27, C30, C32, C34, and C37 with molecular weights (as methyl esters) of 424, 466, 494, 522, and 564, respectively. The stereochemistry of the methyl branches of the mycocerosates have R absolute configuration. The glycolipid is highly antigenic and appears to be specific for M. haemophilum. There are intriguing similarities between the product from M. haemophilum and the well-known phenolic glycolipid I of Mycobacterium leprae, a matter that is discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1868054     DOI: 10.1021/bi00245a015

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

1.  Distribution of sigma factors delineates segregation of virulent and avirulent Mycobacterium.

Authors:  Aayatti Mallick Gupta; Sukhendu Mandal
Journal:  Arch Microbiol       Date:  2021-01-11       Impact factor: 2.552

Review 2.  Mycobacterium haemophilum: microbiology and expanding clinical and geographic spectra of disease in humans.

Authors:  M A Saubolle; T E Kiehn; M H White; M F Rudinsky; D Armstrong
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

Review 3.  Clinical manifestations, diagnosis, and treatment of Mycobacterium haemophilum infections.

Authors:  Jerome A Lindeboom; Lesla E S Bruijnesteijn van Coppenraet; Dick van Soolingen; Jan M Prins; Eduard J Kuijper
Journal:  Clin Microbiol Rev       Date:  2011-10       Impact factor: 26.132

Review 4.  Mycobacterium haemophilum: an emerging pathogen.

Authors:  T E Kiehn; M White
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

5.  Structure of N-linked oligosaccharides attached to chlorovirus PBCV-1 major capsid protein reveals unusual class of complex N-glycans.

Authors:  Cristina De Castro; Antonio Molinaro; Francesco Piacente; James R Gurnon; Luisa Sturiale; Angelo Palmigiano; Rosa Lanzetta; Michelangelo Parrilli; Domenico Garozzo; Michela G Tonetti; James L Van Etten
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-05       Impact factor: 11.205

6.  Biochemical properties and fatty acid composition of Mycobacterium haemophilum: study of 16 isolates from Australian patients.

Authors:  F Portaels; D J Dawson; L Larsson; L Rigouts
Journal:  J Clin Microbiol       Date:  1993-01       Impact factor: 5.948

7.  The Complete Genome Sequence of the Emerging Pathogen Mycobacterium haemophilum Explains Its Unique Culture Requirements.

Authors:  JoAnn M Tufariello; Christopher A Kerantzas; Catherine Vilchèze; R Brent Calder; Eric K Nordberg; Jack A Fischer; Travis E Hartman; Eva Yang; Timothy Driscoll; Laura E Cole; Robert Sebra; Shahina B Maqbool; Alice R Wattam; William R Jacobs
Journal:  mBio       Date:  2015-11-17       Impact factor: 7.867

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.